Heartflow (NASDAQ:HTFL) Earns Buy Rating from Analysts at Canaccord Genuity Group

Key Points

• Analysts at Canaccord Genuity Group have initiated coverage of Heartflow (NASDAQ:HTFL) with a "buy" rating and a price target of $35.00, indicating an 11.11% potential upside.
• Heartflow's current stock price is $31.50, with 12-month high and low values of $36.68 and $26.56, respectively.
• The company has been recognized for its innovative use of AI in diagnosing coronary artery disease, with its platform assessing over 400,000 patients as of March 31, 2025.

Canaccord Genuity Group assumed coverage on shares of Heartflow (NASDAQ:HTFL - Free Report) in a report published on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $35.00 price target on the stock.

Separately, Wall Street Zen raised Heartflow to a "hold" rating in a report on Saturday, August 16th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Heartflow presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.80.

Heartflow Stock Performance

NASDAQ:HTFL traded down $3.01 during trading hours on Tuesday, reaching $31.07. 442,043 shares of the stock were exchanged, compared to its average volume of 878,154. Heartflow has a twelve month low of $26.56 and a twelve month high of $36.68.

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.